Clin Cancer Res: Blocking PD1 enhances the efficacy of ICAM1-targeted CAR T cells in the treatment of advanced thyroid cancer.

Advanced thyroid cancer, including poor differentiation and interdessional thyroid cancer (ATC), is a deadly malignant tumor with limited treatment options.
most ATC patients had a poor response to programmed death 1 (PD1) blocking in early clinical trials.
need to explore new treatment options.
this study looked at the expression of PD-L1 (the lien of PD1) and intercellular adhesion molecule 1 (ICAM1) in thyroid tumors and ATC cell lineages, and studied the expression level of PD1 in exosome blood T cells in patients with thyroid cancer.
another.
in ac heterogeneous transplantation model, the single treatment of ICM1 targeted chimline antigen recipient (CAR) T cells and anti-PD1 antibodies, as well as tumor target efficacy and T-cell dynamics of combined therapy, were studied.
advanced thyroid cancer was associated with increased expression of ICAM1 and PD-L1 in tumors and increased expression of PD1 in circulating blood CD8 T cells.
expressions of ICAM1 and PD-L1 in ATC cell lines are regulated by the IFN-JAK2 signaling path.
ICAM1 targeted CAR T cells from healthy donors or patient T-cell sources combined with PD1 blocking, the ability to eliminate targeted tumor cells expressed by ICAM1 is enhanced compared to pure CAR T-cell therapy.
PD1 blocking helps to remove PD-L1 high tumor cloning and inhibits excessive proliferation of CAR T cells, rapidly removing tumor cells from mouse models and extending their survival.
, targeting two IFN-induced, tumor-related antigens (ICAM1 and PD-L1) in complementary ways may be an effective treatment strategy for controlling advanced thyroid cancer.
.